Product Description: Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity[1][2].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Hay CM, et al. Targeting CD73 in the tumor microenvironment with MEDI9447. Oncoimmunology. 2016 Jul 11;5(8):e1208875./[2]Roy S Herbst, et al. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022 Apr 22;JCO2200227.
CAS Number: 1803176-05-7
Molecular Weight: N/A
Compound Purity: 99.80
Research Area: Cancer
Solubility: H2O
Target: CD73
English
Deutsch
